| Name | Tesidolumab |
|---|
| Description | Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Tesidolumab (LFG316) possesses a half-life in humans of approximately 9 days. Tesidolumab (LFG316) binds to a distinct epitope to that of eculizumab and ravulizumab, distant to Arg 885[1]. |
| References |
| No Any Chemical & Physical Properties |